<code id='ED59479D96'></code><style id='ED59479D96'></style>
    • <acronym id='ED59479D96'></acronym>
      <center id='ED59479D96'><center id='ED59479D96'><tfoot id='ED59479D96'></tfoot></center><abbr id='ED59479D96'><dir id='ED59479D96'><tfoot id='ED59479D96'></tfoot><noframes id='ED59479D96'>

    • <optgroup id='ED59479D96'><strike id='ED59479D96'><sup id='ED59479D96'></sup></strike><code id='ED59479D96'></code></optgroup>
        1. <b id='ED59479D96'><label id='ED59479D96'><select id='ED59479D96'><dt id='ED59479D96'><span id='ED59479D96'></span></dt></select></label></b><u id='ED59479D96'></u>
          <i id='ED59479D96'><strike id='ED59479D96'><tt id='ED59479D96'><pre id='ED59479D96'></pre></tt></strike></i>

          knowledge

          knowledge

          author:Wikipedia    Page View:879
          King Street Properties’ Pathway Devens campus. -- biotech coverage from STAT
          Pat Greenhouse/Globe Staff

          MORRISVILLE, N.C. — Ten minutes from the Raleigh airport, the future of biotech is under construction.

          On either side of a new stretch of four-lane highway sit two $1 billion biomanufacturing campuses, which will bring a combined 2.5 million square feet of research and development and advanced manufacturing space to a region that has become the No. 1 place where North America makes prescription drugs.

          advertisement

          One campus, called Pathway Triangle, is being built by a developer from Boston, King Street Properties. King Street — which has projects in Cambridge, Waltham, Allston, and Lexington — is building a similarly vast biomanufacturing campus in Devens. But these days it also sees a land of opportunity 700 miles to the south, in North Carolina.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Sudafed saga points to U.S. issues with evaluating older drugs
          Sudafed saga points to U.S. issues with evaluating older drugs

          PATRICKT.FALLON/AFPviaGettyImagesYouwouldhavebeenforgivenforbeingsurprisedonSept.12whenapanelofadvis

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Would Medicare drug price negotiations stall in a shutdown?

          AlexHogan/STATYou’rereadingthewebeditionofD.C.Diagnosis. Signuphere toreceivethisnewsletterinyourinb